Bionime Corporation

As of June 30, 2026, Bionime Corporation carries a market capitalization of 4.30B, placing it among publicly traded companies globally. Its enterprise value stands at 6.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bionime Corporation's next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Bionime Corporation has 77.33M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.32, and the price-to-book ratio stands at 2.05.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.80 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.52B versus a market cap of 4.30B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bionime Corporation maintains a current ratio of 0.77, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 125.73, indicating elevated leverage, while an interest coverage ratio of -2.00 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Bionime Corporation posted a negative return on equity (ROE) of -14.38, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -5.06, reflecting losses generated across the asset base. The company generates approximately 1.63M in revenue per employee across its workforce of 1,056.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.21 indicates how many times Bionime Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Bionime Corporation recorded an income tax benefit of -94.33M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -377.77M and -286.32M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Bionime Corporation's stock has declined approximately 3.69% over the past 52 weeks. The 50-day moving average sits at 57.16, while the 200-day moving average is 58.04.

Over the twelve months ended June 30, 2026, Bionime Corporation generated 1.72B in revenue and converted that into -286.32M in net income, yielding earnings per share of -3.96. EBITDA reached -127.45M, while operating income came in at -304.87M.

As of June 30, 2026, Bionime Corporation holds 444.78M in cash and equivalents against 2.66B in total debt, resulting in a net debt position of 2.25B. Total book value stands at 2.10B, with working capital of -464.09M providing operational flexibility.

Bionime Corporation produced 125.91M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -191.10M in capital expenditures, free cash flow totaled -65.18M - equivalent to -0.91 per share.

Over the twelve months ended June 30, 2026, Bionime Corporation posted a gross margin of 33.55, reflecting its pricing power and cost economics. The operating margin of -17.75 and net profit margin of -16.67 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.64: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.77, meaning Bionime Corporation raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Bionime Corporation's most recent stock split took place on January 8, 2026 with a 205:207 split ratio.

As of June 30, 2026, Bionime Corporation has an Altman Z-Score of 0.72, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.